Mom's Garden Unveils Innovative Collagen Product at CICPE 2026 Exhibition

On April 13, 2026, the 6th China International Consumer Products Expo (CICPE) kicked off successfully in Hainan, showcasing the latest advancements in consumer health products. Among the highlights was the German brand Mom's Garden, renowned for its focus on bone health, which introduced its newest innovation: 'iFlex'. This product aims to meet the increasingly sophisticated health demands of Chinese consumers, particularly concerning joint care.

In the past, traditional joint care primarily focused on superficial symptom relief. However, the dedicated research and development team at Mom's Garden has identified that the root cause of joint issues lies in the degradation of cartilage structure. The newly developed 'iFlex', based on a patented German formula, effectively addresses inflammatory responses while deeply repairing the collagen fiber network within cartilage, acting like a 'steel structure' that ensures durability. This dual action not only targets the underlying causes of joint problems but also restores structural integrity more effectively than previous products.

Olga Stepanko, the global brand director of Mom's Garden, highlighted the brand's commitment to improving the quality of life for individuals suffering from joint pain. She expressed, "Joint pain significantly curtails individuals' ability to enjoy a better quality of life. The ultimate goal of scientific innovation should not merely be to gather data but to empower individuals with true freedom of movement."

Building upon its previous initiatives, which included expert recommendations for bone and joint health aimed at middle-aged and older adults, Mom's Garden demonstrated its commitment to scientific evidence and local adaptation in China. During the expo, the brand conducted roundtable discussions to engage with local stakeholders, reinforcing its ties to the community.

Moving forward, Mom's Garden intends to deepen collaborative efforts in research and development between China and Germany. The brand is committed to optimizing its product portfolio based on evidence and accelerating its local development strategy to respond even more effectively to consumer needs. The launch of 'iFlex' represents a significant step in this journey, showcasing the brand's innovative approach to joint health.

In conclusion, the presentation of 'iFlex' at the CICPE marks a significant moment for Mom's Garden as it not only introduces a revolutionary product to the market but also solidifies its position as a leading authority in bone health solutions. By prioritizing evidence-based strategies and the elimination of core issues in joint health, Mom's Garden is set to transform the landscape of joint care products in China and beyond. The company's future endeavors will likely continue to reflect its dedication to enhancing consumer well-being through innovative health solutions.